Ubs Group Ag Citius Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 605 shares of CTXR stock, worth $1,893. This represents 0.0% of its overall portfolio holdings.

Number of Shares

605

Previous 62,779 99.04%

Holding current value

$1,893

Previous $36,000 100.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.48 - $1.02 $29,843 - $63,417	-62,174 Reduced 99.04%	605 $0
Q2 2024 Aug 13, 2024	SELL	$0.58 - $1.03 $41,663 - $73,989	-71,834 Reduced 53.36%	62,779 $36,000
Q1 2024 May 13, 2024	SELL	$0.6 - $0.9 $1,740 - $2,610	-2,900 Reduced 2.11%	134,613 $121,000
Q4 2023 Feb 09, 2024	BUY	$0.65 - $0.86 $25,667 - $33,960	39,489 Added 40.29%	137,513 $104,000
Q3 2023 Nov 09, 2023	BUY	$0.65 - $1.25 $17,482 - $33,620	26,896 Added 37.81%	98,024 $66,000
Q2 2023 Aug 11, 2023	BUY	$1.08 - $1.65 $76,422 - $116,757	70,762 Added 19333.88%	71,128 $85,000
Q1 2023 May 12, 2023	BUY	$0.78 - $1.42 $285 - $519	366 New	366 $0
Q2 2022 Aug 10, 2022	SELL	$0.88 - $1.87 $20,327 - $43,195	-23,099 Reduced 95.33%	1,132 $1,000
Q1 2022 May 16, 2022	SELL	$1.38 - $1.89 $101,376 - $138,841	-73,461 Reduced 75.2%	24,231 $43,000
Q4 2021 Feb 14, 2022	BUY	$1.51 - $2.2 $61,804 - $90,046	40,930 Added 72.11%	97,692 $150,000
Q3 2021 Nov 15, 2021	BUY	$1.74 - $2.6 $16,824 - $25,139	9,669 Added 20.53%	56,762 $115,000
Q2 2021 Aug 13, 2021	SELL	$1.51 - $4.23 $99,509 - $278,757	-65,900 Reduced 58.32%	47,093 $164,000
Q1 2021 May 12, 2021	BUY	$1.04 - $2.34 $11,243 - $25,297	10,811 Added 10.58%	112,993 $201,000
Q4 2020 Feb 11, 2021	BUY	$0.9 - $1.2 $91,963 - $122,618	102,182 New	102,182 $104,000
Q3 2020 Nov 12, 2020	SELL	$0.83 - $1.51 $6,452 - $11,738	-7,774 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$0.65 - $1.45 $5,053 - $11,272	7,774 New	7,774 $9,000
Q3 2019 Nov 14, 2019	SELL	$0.72 - $1.38 $2,625 - $5,032	-3,647 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$0.93 - $1.38 $3,391 - $5,032	3,647 New	3,647 $4,000
Q1 2019 May 14, 2019	SELL	$0.86 - $1.53 $571 - $1,017	-665 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$0.99 - $1.89 $658 - $1,256	665 New	665 $1,000
Q3 2018 Nov 14, 2018	SELL	$1.14 - $3.09 $2,932 - $7,947	-2,572 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$2.14 - $3.12 $6,362 - $9,275	-2,973 Reduced 53.62%	2,572 $6,000
Q1 2018 May 15, 2018	BUY	$2.84 - $4.46 $11,473 - $18,018	4,040 Added 268.44%	5,545 $17,000
Q4 2017 Feb 14, 2018	SELL	$2.65 - $5.1 $1,017 - $1,958	-384 Reduced 20.33%	1,505 $6,000
Q3 2017 Nov 14, 2017	BUY	$2.69 - $4.03 $5,081 - $7,612	1,889	1,889 $6,000

Others Institutions Holding CTXR

# of Institutions

Shares Held

23.7M

Call Options Held

83.1K

Put Options Held

32.1K

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $457M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account